2015 Proves to be a Disappointing Year for Dose CMO Industry Growth
PharmSource report expects growth rate to continue slowing as challenges intensify
Fairfax, VA, USA (September 9, 2016) – Growth of the bio/pharmaceutical contract manufacturing sector is likely to continue to slow relative to overall industry growth despite the significant increase in New Active Substances launched from 2014 onwards.
This projection is well authenticated in a report published by the industry’s preeminent expert, PharmSource Information Services, Inc. Key reasons for the slowing industry growth rate are the appreciation of the US dollar against the Euro, client losses and regulatory compliance issues.
The new report, Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook–2016 Edition, is the bio/pharmaceutical industry’s singular authoritative analysis of the performance of the dose CMO business.
The expert analysis is derived from PharmSource’s proprietary database of global contract manufacturers. It reflects the company’s deep knowledge of contract drug development and manufacturing, as well as its relationships with the industry’s leading participants.
Far-reaching insights detailed in Contract Dose Manufacturing Industry by the Numbers–2016 Edition include:
- The contract dose manufacturing industry generated revenues of $18.5 billion in 2015.
- Acquisitions of facilities from bio/pharmaceutical companies were responsible for a significant share of industry growth.
- Consolidation remained a feature of the sector in 2015 with eight CMO acquisitions.
- Going forward, CMO industry growth will be challenged by global bio/pharma companies declining propensity to outsource new approvals, along with shrinking unit volume per product, too much capacity relative to market size and declining prices.
The information in this data-rich report will help CMOs and their investors make informed critical strategic decisions. Bio/pharmaceutical sourcing and procurement executives will find this intelligence invaluable for assessing their current CMO network and developing long-term sourcing strategies.
PharmSource is the recognized unbiased authority of knowledge about the global bio/pharmaceutical contract services industry. The company’s proprietary publications, database platforms, research tools and analyses inform buyers and sellers of bio/pharma contract services about industry trends, activities and partnership opportunities.
Since 1996, bio/pharmaceutical companies, CMOs, CDMOs and CROs worldwide have looked to PharmSource for expert information delivered with timeliness and integrity. To learn why 80% of the largest bio/pharmaceutical companies, and 80% of the top global CMOs, rely on PharmSource, visit www.pharmsource.com.